A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition.
Angiotensin-Converting Enzyme 2
Animals
Antiviral Agents
/ pharmacology
Betacoronavirus
/ genetics
COVID-19
COVID-19 Vaccines
Cell Line
Chlorocebus aethiops
Coronavirus Infections
/ drug therapy
Drug Evaluation, Preclinical
Host Microbial Interactions
/ drug effects
Humans
Mutation
Neutralization Tests
Pandemics
/ prevention & control
Peptidyl-Dipeptidase A
/ genetics
Pneumonia, Viral
/ prevention & control
Receptors, Virus
/ genetics
Recombination, Genetic
SARS-CoV-2
Serine Endopeptidases
/ physiology
Spike Glycoprotein, Coronavirus
/ genetics
Vero Cells
Vesicular stomatitis Indiana virus
/ genetics
Viral Vaccines
/ genetics
Virus Internalization
Virus Replication
/ genetics
COVID-19 Drug Treatment
ACE2
COVID-19
SARS-CoV-2
VSV
antiviral drugs
convalescent plasma
neutralization assay
neutralizing antibody
serology
surrogate
Journal
Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316
Informations de publication
Date de publication:
09 09 2020
09 09 2020
Historique:
received:
19
05
2020
revised:
16
06
2020
accepted:
23
06
2020
pubmed:
2
8
2020
medline:
22
9
2020
entrez:
2
8
2020
Statut:
ppublish
Résumé
There is an urgent need for vaccines and therapeutics to prevent and treat COVID-19. Rapid SARS-CoV-2 countermeasure development is contingent on the availability of robust, scalable, and readily deployable surrogate viral assays to screen antiviral humoral responses, define correlates of immune protection, and down-select candidate antivirals. Here, we generate a highly infectious recombinant vesicular stomatitis virus (VSV) bearing the SARS-CoV-2 spike glycoprotein S as its sole entry glycoprotein and show that this recombinant virus, rVSV-SARS-CoV-2 S, closely resembles SARS-CoV-2 in its entry-related properties. The neutralizing activities of a large panel of COVID-19 convalescent sera can be assessed in a high-throughput fluorescent reporter assay with rVSV-SARS-CoV-2 S, and neutralization of rVSV-SARS-CoV-2 S and authentic SARS-CoV-2 by spike-specific antibodies in these antisera is highly correlated. Our findings underscore the utility of rVSV-SARS-CoV-2 S for the development of spike-specific therapeutics and for mechanistic studies of viral entry and its inhibition.
Identifiants
pubmed: 32738193
pii: S1931-3128(20)30361-9
doi: 10.1016/j.chom.2020.06.020
pmc: PMC7332447
pii:
doi:
Substances chimiques
Antiviral Agents
0
COVID-19 Vaccines
0
Receptors, Virus
0
Spike Glycoprotein, Coronavirus
0
Viral Vaccines
0
spike protein, SARS-CoV-2
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Serine Endopeptidases
EC 3.4.21.-
TMPRSS2 protein, human
EC 3.4.21.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
486-496.e6Subventions
Organisme : NIAID NIH HHS
ID : R01 AI123654
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI125462
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007288
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI142777
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132633
Pays : United States
Organisme : NIAID NIH HHS
ID : F30 AI150055
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI141367
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI143453
Pays : United States
Commentaires et corrections
Type : UpdateOf
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests K.C. is a member of the scientific advisory board of Integrum Scientific, LLC.
Références
J Virol. 2005 Dec;79(23):14614-21
pubmed: 16282461
J Virol. 2010 Jan;84(1):163-75
pubmed: 19846533
J Virol. 2007 Mar;81(5):2418-28
pubmed: 17166901
Front Microbiol. 2019 Apr 26;10:856
pubmed: 31105663
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Lancet Respir Med. 2020 Jul;8(7):687-695
pubmed: 32386571
Nat Med. 2020 Sep;26(9):1422-1427
pubmed: 32651581
Nature. 2018 Nov;563(7732):559-563
pubmed: 30464266
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Virol. 2019 Oct 15;93(21):
pubmed: 31391268
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8388-92
pubmed: 7667300
J Virol. 2010 Jun;84(11):5605-14
pubmed: 20237084
Sci Immunol. 2020 May 13;5(47):
pubmed: 32404436
J Virol. 2005 Mar;79(6):3846-50
pubmed: 15731278
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
J Virol. 2012 Jun;86(12):6537-45
pubmed: 22496216
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
J Virol. 2009 Apr;83(7):3200-11
pubmed: 19158246
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Biochimie. 2017 Nov;142:1-10
pubmed: 28778717
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Nat Microbiol. 2020 Apr;5(4):562-569
pubmed: 32094589
J Med Virol. 2006 Dec;78(12):1509-12
pubmed: 17063504
J Virol Methods. 2006 Jul;135(1):91-101
pubmed: 16569439
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Antiviral Res. 2015 Apr;116:76-84
pubmed: 25666761
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
J Gen Virol. 2005 Aug;86(Pt 8):2269-2274
pubmed: 16033974
J Clin Invest. 2020 Apr 1;130(4):1545-1548
pubmed: 32167489
Science. 2020 Jun 12;368(6496):1274-1278
pubmed: 32404477
Science. 2013 Apr 26;340(6131):479-83
pubmed: 23519211
Emerg Infect Dis. 2020 Jun;26(6):1266-1273
pubmed: 32160149
Virology. 2008 Jun 20;376(1):165-72
pubmed: 18396306
Antiviral Res. 2018 Feb;150:30-38
pubmed: 29246504
Science. 2020 May 29;368(6494):1012-1015
pubmed: 32303590
Emerg Microbes Infect. 2020 Dec;9(1):2105-2113
pubmed: 32893735
Virology. 2005 Sep 30;340(2):174-82
pubmed: 16043204
Nat Commun. 2020 Apr 24;11(1):2070
pubmed: 32332765
mBio. 2019 Jan 8;10(1):
pubmed: 30622188
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
Mol Ther Nucleic Acids. 2016 May 24;5:e321
pubmed: 27219515
mBio. 2015 Jun 30;6(4):e00801
pubmed: 26126854
PLoS One. 2015 Oct 20;10(10):e0141169
pubmed: 26485396
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
J Med Virol. 2020 Sep;92(9):1609-1614
pubmed: 32275081
Nucleic Acids Res. 1990 Jun 25;18(12):3587-96
pubmed: 2194165
Trends Mol Med. 2009 Jul;15(7):303-12
pubmed: 19581128
Clin Infect Dis. 2020 Sep 12;71(6):1400-1409
pubmed: 32270184
J Gen Virol. 2016 Aug;97(8):1853-1864
pubmed: 27145752
RNA. 2003 Apr;9(4):493-501
pubmed: 12649500
Cell Host Microbe. 2017 Nov 8;22(5):688-696.e5
pubmed: 29120745
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Curr Top Microbiol Immunol. 2014;385:3-34
pubmed: 25031010
J Virol. 2003 Aug;77(16):8801-11
pubmed: 12885899
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
Life Sci Alliance. 2020 Jul 23;3(9):
pubmed: 32703818
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855